丙型肝炎病毒治疗：化繁为简，优化难点。
Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
机构信息
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
J Infect Dis. 2020 Nov 27;222(Suppl 9):S745-S757. doi: 10.1093/infdis/jiaa534.
Abstract
The availability of safe, efficacious, oral direct-acting antivirals (DAAs) have ushered in a new era of hepatitis C treatment with potential to eliminate hepatitis C as a public health threat. To achieve population-level effectiveness of these oral DAAs, hepatitis C treatment by a wide range of providers in different settings will be essential to increase the number of persons treated. We provide a clinical review of hepatitis C treatment with a focus on practical tools for management of hepatitis C in majority of currently infected individuals who can be easily cured and optimization of treatment for those in whom treatment may not be as simple.
摘要
安全、有效的口服直接作用抗病毒药物（DAAs）的出现开创了丙型肝炎治疗的新时代，有可能消除丙型肝炎这一公共卫生威胁。为了实现这些口服 DAA 在人群中的有效性，广泛的提供者在不同的环境中进行丙型肝炎治疗对于增加治疗人数至关重要。我们提供了丙型肝炎治疗的临床综述，重点是管理目前大多数可轻易治愈的感染者的丙型肝炎的实用工具，以及优化那些治疗可能不那么简单的患者的治疗。
相似文献
1
Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.丙型肝炎病毒治疗：化繁为简，优化难点。
J Infect Dis. 2020 Nov 27;222(Suppl 9):S745-S757. doi: 10.1093/infdis/jiaa534.
2
Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.高效丙型肝炎病毒直接抗病毒治疗时代的丙型肝炎/艾滋病病毒合并感染管理
Clin Infect Dis. 2016 Jul 15;63 Suppl 1(Suppl 1):S3-S11. doi: 10.1093/cid/ciw219.
3
Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.HIV感染者丙型肝炎病毒治疗中的药理学考量
Clin Infect Dis. 2016 Jul 15;63 Suppl 1(Suppl 1):S12-23. doi: 10.1093/cid/ciw220.
4
Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.丙型肝炎直接作用抗病毒药物时代的高危供肝肝移植。
Exp Clin Transplant. 2020 Oct;18(5):605-611. doi: 10.6002/ect.2019.0065. Epub 2019 Jul 19.
5
Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.直接作用抗病毒药物时代欧洲丙型肝炎负担和治疗趋势的变化：建模研究。
BMJ Open. 2019 Jun 11;9(6):e026726. doi: 10.1136/bmjopen-2018-026726.
6
Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.德国慢性丙型肝炎感染的真实世界治疗：2010-2015 年药物处方数据分析。
J Hepatol. 2017 Jul;67(1):15-22. doi: 10.1016/j.jhep.2017.01.024. Epub 2017 Feb 9.
7
A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.人群方法进行疾病管理：在大型医疗体系中使用丙型肝炎直接作用抗病毒药物。
J Manag Care Spec Pharm. 2014 Jun;20(6):533-40. doi: 10.18553/jmcp.2014.20.6.533.
8
Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.使用印度可获得的通用直接作用抗病毒药物治疗丙型肝炎的成本效益。
PLoS One. 2017 May 17;12(5):e0176503. doi: 10.1371/journal.pone.0176503. eCollection 2017.
9
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals.革新丙型肝炎治疗：新一代直接作用抗病毒药物。
Expert Opin Pharmacother. 2024 May;25(7):833-852. doi: 10.1080/14656566.2024.2358139. Epub 2024 May 27.
10
Simplified treatment of hepatitis C: another strategy to overcome the barriers to its elimination.简化丙型肝炎治疗：消除丙型肝炎障碍的另一策略。
Medicina (B Aires). 2021;81(2):252-256.
引用本文的文献
1
Sustained virological response in chronic hepatitis C patients by direct-acting antiviral treatment significantly reduces liver stiffness over 24 weeks posttreatment.直接作用抗病毒治疗可使慢性丙型肝炎患者获得持续病毒学应答，显著降低治疗后 24 周时的肝硬度。
Medicine (Baltimore). 2024 May 10;103(19):e38096. doi: 10.1097/MD.0000000000038096.
2
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.基于台湾全国范围内的数据，为非专业医护人员简化丙型肝炎病毒治疗的算法。
Hepatol Int. 2024 Apr;18(2):461-475. doi: 10.1007/s12072-023-10609-7. Epub 2024 Jan 21.
3
Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea.厄立特里亚慢性丙型肝炎病毒感染直接作用抗病毒药物的真实世界治疗结果和患者生存率。
Sci Rep. 2023 Nov 27;13(1):20792. doi: 10.1038/s41598-023-47258-7.
4
Nurse-led initiation of hepatitis C care in rural Cambodia.柬埔寨农村地区的护士主导的丙型肝炎治疗护理启动。
Bull World Health Organ. 2023 Apr 1;101(4):262-270. doi: 10.2471/BLT.22.288956. Epub 2023 Feb 21.
5
24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy.直接作用抗病毒治疗后 HCV 单感染和 HCV/HIV 合并感染患者非侵入性肝纤维化标志物 24 个月的下降。
Sci Rep. 2022 Mar 9;12(1):3828. doi: 10.1038/s41598-022-07548-y.
6
Present and future management of viral hepatitis.病毒性肝炎的现状与未来管理。
World J Gastroenterol. 2021 Dec 21;27(47):8081-8102. doi: 10.3748/wjg.v27.i47.8081.
7
Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).探索澳大利亚墨尔本 HCV 病毒检测和治疗参与度的时间变化：一项纵向队列研究的研究方案（EC-经验队列研究）。
BMJ Open. 2022 Jan 4;12(1):e057618. doi: 10.1136/bmjopen-2021-057618.
8
Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.应用 AASLD-IDSA 简化治疗算法对丙型肝炎的实际管理的经济影响。
J Manag Care Spec Pharm. 2022 Jan;28(1):48-57. doi: 10.18553/jmcp.2021.21246. Epub 2021 Oct 22.
本文引用的文献
1
Public Health Clinic-Based Hepatitis C Treatment.基于公共卫生诊所的丙型肝炎治疗。
Am J Prev Med. 2020 Sep;59(3):420-427. doi: 10.1016/j.amepre.2020.03.006. Epub 2020 May 16.
2
Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis.用于治疗慢性丙型肝炎病毒感染的泛基因型直接作用抗病毒药物：一项系统文献综述和荟萃分析。
EClinicalMedicine. 2020 Jan 5;18:100237. doi: 10.1016/j.eclinm.2019.12.007. eCollection 2020 Jan.
3
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新：美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
4
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.格卡瑞韦/哌仑他韦治疗初治慢性 HCV 基因型 1-6 且代偿期肝硬化患者 8 周：EXPEDITION-8 试验。
J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. Epub 2019 Nov 2.
5
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.格卡瑞韦哌仑他韦在 NS5A 抑制剂联合索磷布韦治疗失败的基因 1 型丙型肝炎病毒感染患者中的疗效。
Gastroenterology. 2019 Dec;157(6):1506-1517.e1. doi: 10.1053/j.gastro.2019.08.008. Epub 2019 Aug 8.
6
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.慢性丙型肝炎病毒感染患者持续病毒学应答对患者报告结局的长期益处。
Clin Gastroenterol Hepatol. 2020 Feb;18(2):468-476.e11. doi: 10.1016/j.cgh.2019.07.047. Epub 2019 Jul 31.
7
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.在基层医疗与医院为基础的医疗之间治疗丙型肝炎的结果比较：一项针对注射吸毒者的随机对照试验。
Clin Infect Dis. 2020 Apr 15;70(9):1900-1906. doi: 10.1093/cid/ciz546.
8
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.索磷布韦/维帕他韦/沃西拉帕韦用于慢性丙型肝炎感染中格卡瑞韦/哌仑他韦治疗失败的既往史
Am J Gastroenterol. 2019 Sep;114(9):1550-1552. doi: 10.14309/ajg.0000000000000248.
9
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.无肝硬化的日本和海外丙型肝炎病毒 1 或 2 型感染患者 8 周 glecaprevir/pibrentasvir 的综合分析。
J Gastroenterol. 2019 Aug;54(8):752-761. doi: 10.1007/s00535-019-01569-7. Epub 2019 Mar 13.
10
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.接受glecaprevir/pibrentasvir治疗丙型肝炎病毒感染失败患者的再治疗。
J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.
Zotero 插件